ロード中...
Novel agents for advanced pancreatic cancer
Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemothe...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4741843/ https://ncbi.nlm.nih.gov/pubmed/26369833 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|